Vera Therapeutics, Inc.
VERA
$22.57
-$0.04-0.18%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 62.92M | 49.00M | 41.00M | 31.67M | 27.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 236.05M | 193.25M | 167.17M | 145.28M | 117.24M |
| Operating Income | -236.05M | -193.25M | -167.17M | -145.28M | -117.24M |
| Income Before Tax | -218.28M | -175.46M | -152.15M | -134.38M | -107.85M |
| Income Tax Expenses | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Earnings from Continuing Operations | -218.28 | -175.46 | -152.15 | -134.38 | -107.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -218.28M | -175.46M | -152.15M | -134.38M | -107.85M |
| EBIT | -236.05M | -193.25M | -167.17M | -145.28M | -117.24M |
| EBITDA | -235.77M | -193.07M | -167.07M | -145.23M | -117.20M |
| EPS Basic | -3.58 | -2.99 | -2.74 | -2.60 | -2.20 |
| Normalized Basic EPS | -2.24 | -1.87 | -1.71 | -1.62 | -1.38 |
| EPS Diluted | -3.58 | -2.99 | -2.74 | -2.60 | -2.20 |
| Normalized Diluted EPS | -2.24 | -1.87 | -1.71 | -1.62 | -1.38 |
| Average Basic Shares Outstanding | 243.05M | 233.99M | 221.29M | 205.05M | 194.52M |
| Average Diluted Shares Outstanding | 243.05M | 233.99M | 221.29M | 205.05M | 194.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |